Sanofi pays up to USD 1bn for new multiple myeloma therapy

Following a licensing agreement with Eureka Therapeutics, Sanofi has acquired another drug candidate for multiple myeloma to join its portfolio alongside Sarclisa.
Photo: CHARLES PLATIAU/Reuters / X00217
Photo: CHARLES PLATIAU/Reuters / X00217
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

Sanofi is paying an undisclosed amount to forge a new license agreement with Eureka Therapeutics. However, the value of the deal might reach USD 1bn in subsequent milestone payments, according to a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading